Vanessa, Jared & Adam are joined by Katy Wong, National Pharmacy Leader for Brown & Brown, to discuss the latest trends in transformative therapies and pharmacy benefit management (PBM). Katy highlights how GLP-1s, specialty drugs and gene therapies will continue to drive up costs and how biosimilars are expected to help offset these expenses to health plans.
The team dives into the challenging landscape facing the traditional PBM model in 2025. Transparency and accountability remain critical for plan sponsors, opening the door for disruptor PBMs and non-traditional PBM delivery models. The team also addresses high-cost drugs in the pipeline, transparency concerns and the current regulatory and legislative dynamics impacting plan sponsors.
Check out our 2025 Employee Benefits Market Trends
Connect with the hosts: